Answers are grounded in this paper and cite their sources.
Despite some success, many patients do not benefit from immunotherapy. New strategies to improve clinical efficacy include identification of novel immune-checkpoint (IC) targets or a combination of immunotherapy with antiangiogenic treatments. Here, we propose the therapeutic use of IC, HLA-G/LILRB, and explore its enhanced synergistic antitumor activity when combined with antiangiogenic therapies.
No takes yet. Share an insight, caveat, or question.
Carosella et al. (2021) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: